Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients

NCT02266628 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT02266628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02266628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients
Lead sponsor
Novavax
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
March 31, 2016
Enrollment
1,599 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)